Identification

Name
Calcium Citrate
Accession Number
DB11093
Type
Small Molecule
Groups
Approved
Description

Calcium citrate is a salt typically used as a source of calcium in a variety of over the counter supplements.

Structure
Thumb
Synonyms
  • tricalcium citrate
External IDs
E-333(III) / INS NO.333(III) / INS-333(III)
Product Ingredients
IngredientUNIICASInChI Key
Calcium citrate tetrahydrateMLM29U2X855785-44-4LNIZKKFWMDARJV-UHFFFAOYSA-H
Product Images
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Calcium Citrate Tab 350mgTablet350 mgOralGahler Enterprises Ltd.1987-12-312007-08-07Canada
Citracal Liquitab - EvtTablet, effervescent500 mgOralMission Pharmacal1996-12-172003-07-15Canada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Calcium Citrate W Vitamin D TabCalcium Citrate (250 mg) + Ergocalciferol (100 unit)TabletOralNutri Dyn Products Ltd.1994-12-311996-09-09Canada
Citranatal Harmony 2.1Calcium Citrate (104 mg/1) + Iron (29 mg/1)Capsule, gelatin coatedOralMission Pharmacal2013-01-21Not applicableUs
Usana Active CalciumCalcium Citrate (77.9 mg/1) + Calcium Carbonate (356 mg/1) + Cholecalciferol (200 [iU]/1) + Magnesium citrate (44.4 mg/1) + Magnesium oxide (158 mg/1)Tablet, chewableOralUsana Health Sciences, Inc.2012-03-282018-01-13Us
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
CitraNatal 90 DHACalcium Citrate (159 mg/1) + Cupric oxide (2 mg/1) + D-alpha-Tocopherol acetate (30 [iU]/1) + Docusate sodium (50 mg/1) + Folic Acid (1 mg/1) + Iron (85 mg/1) + Ferrous gluconate (5 mg/1) + Nicotinamide (20 mg/1) + Potassium Iodide (150 ug/1) + Pyridoxine hydrochloride (20 mg/1) + Riboflavin (3.4 mg/1) + Thiamine (3 mg/1) + Thiamine mononitrate (4.54 mg/1) + Vitamin C (120 mg/1) + Vitamin D (400 [iU]/1) + Zinc oxide (25 mg/1)TabletOralMission Pharmacal2014-04-11Not applicableUs
CitraNatal B-CalmCalcium Citrate + Cholecalciferol + Folic Acid + Iron + Pyridoxine hydrochloride + Vitamin CKitMission Pharmacal2010-02-10Not applicableUs
CitraNatal DHACalcium Citrate (125 mg/1) + Cupric oxide (2 mg/1) + D-alpha-Tocopherol acetate (30 [iU]/1) + Docusate sodium (50 mg/1) + Folic Acid (1 mg/1) + Iron (27 mg/1) + Nicotinamide (20 mg/1) + Potassium Iodide (150 mg/1) + Pyridoxine hydrochloride (20 mg/1) + Riboflavin (3.4 mg/1) + Thiamine (3 mg/1) + Vitamin C (120 mg/1) + Vitamin D (400 [iU]/1) + Zinc oxide (25 mg/1)TabletOralMission Pharmacal2007-11-20Not applicableUs
CitraNatal Harmony 3.0Calcium Citrate (104 mg/1) + Cholecalciferol (400 [iU]/1) + Doconexent (260 mg/1) + Docusate sodium (50 mg/1) + Folic Acid (1 mg/1) + Iron (27 mg/1) + Pyridoxine (25 mg/1) + Vitamin E (30 [iU]/1)Capsule, gelatin coatedOralMission Pharmacal2014-03-21Not applicableUs
CitraNatal MedleyCalcium Citrate (62 mg/1) + Cholecalciferol (200 [iU]/1) + Doconexent (200 mg/1) + Folic Acid (1 mg/1) + Ferrous fumarate (2 mg/1) + Iron (27 mg/1) + Pyridoxine (12.5 mg/1) + Vitamin E (15 [iU]/1)Capsule, gelatin coatedOralMission Pharmacal2018-03-20Not applicableUs
CitraNatal RxCalcium Citrate (125 mg/1) + Cupric oxide (2 mg/1) + D-alpha-Tocopherol acetate (30 [iU]/1) + Docusate sodium (50 mg/1) + Folic Acid (1 mg/1) + Iron (27 mg/1) + Nicotinamide (20 mg/1) + Potassium Iodide (150 mg/1) + Pyridoxine hydrochloride (20 mg/1) + Riboflavin (3.4 mg/1) + Thiamine (3 mg/1) + Vitamin C (120 mg/1) + Vitamin D (400 [iU]/1) + Zinc oxide (25 mg/1)TabletOralMission Pharmacal2007-11-26Not applicableUs
CitraNatal RxCalcium Citrate (124 mg/1) + Cupric oxide (2 mg/1) + D-alpha-Tocopherol acetate (30 [iU]/1) + Folic Acid (1 mg/1) + Iron (27 mg/1) + Nicotinamide (20 mg/1) + Potassium Iodide (150 mg/1) + Pyridoxine hydrochloride (20 mg/1) + Riboflavin (3.4 mg/1) + Thiamine (3 mg/1) + Vitamin C (120 mg/1) + Vitamin D (400 [iU]/1) + Zinc oxide (25 mg/1)TabletOralMission Pharmacal2014-08-11Not applicableUs
FoleneCalcium Citrate (200 mg/1) + Acetylcysteine magnesium (100 mg/1) + Cholecalciferol (3775 [iU]/1) + Levomefolic acid (2 mg/1) + Magnesium citrate (500 mg/1)CapsuleOralGm Pharmaceuticals2016-08-102017-03-07Us
Foltabs PrenatalCalcium Citrate (125 mg/1) + Cholecalciferol (400 [iU]/1) + Cupric oxide (2 mg/1) + Docusate sodium (50 mg/1) + Folic Acid (1 mg/1) + Iron (14 mg/1) + Ferrous gluconate (13 mg/1) + Nicotinamide (20 mg/1) + Potassium Iodide (150 ug/1) + Pyridoxine hydrochloride (30 mg/1) + Riboflavin (3.4 mg/1) + Thiamine mononitrate (3 mg/1) + Vitamin C (120 mg/1) + Vitamin E (30 [iU]/1) + Zinc oxide (25 mg/1)TabletOralMidlothian Laboratories2009-01-012017-12-22Us
INATAL UltraCalcium Citrate (200 mg/1) + Cholecalciferol (400 [iU]/1) + Cupric oxide (2 mg/1) + Cyanocobalamin (12 ug/1) + D-alpha-Tocopherol acetate (30 [iU]/1) + Docusate sodium (50 mg/1) + Folic Acid (1 mg/1) + Iron (90 mg/1) + Nicotinamide (20 mg/1) + Potassium Iodide (150 ug/1) + Pyridoxine hydrochloride (20 mg/1) + Riboflavin (3.4 mg/1) + Thiamine mononitrate (3 mg/1) + Vitamin A (2700 [iU]/1) + Vitamin C (120 mg/1) + Zinc oxide (25 mg/1)Tablet, coatedOralNnodum Pharmaceuticals2005-06-20Not applicableUs
Categories
UNII
86117BWO7P
CAS number
813-94-5
Weight
Average: 498.432
Monoisotopic: 497.8948277
Chemical Formula
C12H10Ca3O14
InChI Key
FNAQSUUGMSOBHW-UHFFFAOYSA-H
InChI
InChI=1S/2C6H8O7.3Ca/c2*7-3(8)1-6(13,5(11)12)2-4(9)10;;;/h2*13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;/q;;3*+2/p-6
IUPAC Name
tricalcium bis(2-hydroxypropane-1,2,3-tricarboxylate)
SMILES
[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O

Pharmacology

Indication

For use as an over the counter calcium supplement.

Associated Conditions
Pharmacodynamics

Increases plasma calcium levels leading to a decrease in calcium flux and increase in calcium deposition into bone [3]

Mechanism of action

Calcium citrate increases plasma calcium levels. This reduces calcium flux from osteocyte activity by reducing the secretion of parathyroid hormone (PTH) [3]. Calcium does this by stimulating a G-protein coupled calcium receptor on the surface of parathyroid cells. The reduction in calcium flux increases the amount of calcium deposited in bone resulting in an increase in bone mineral density. The reduction in PTH secretion also reduces the amount of vitamin D metabolized to its active form, calcidiol. Since calcidiol increases the expression of calcium dependent ATPases and transient receptor potential cation channel subfamily V member 6 (TRPV6) both of which are involved in calcium uptake from the gut, a reduction in calcidiol results in less calcium absorption. Additionally, TRPV5, the channel responsible for calcium reabsorption in the kidney, is downregulated when PTH secretion is reduced thus increasing calcium excretion via the kidneys. Another hormone, calitonin, is likely involved in the reduction of bone resorption during periods of high plasma calcium.

TargetActionsOrganism
AExtracellular calcium-sensing receptor
agonist
Human
NCalreticulin
ligand
Human
UCalcium and integrin-binding protein 1
ligand
Homo sapiens
UProgrammed cell death protein 6
agonist
Human
USorcin
ligand
Homo sapiens
UCalcineurin B homologous protein 1
agonist
Homo sapiens
NSPARC
ligand
Human
NCalnexin
ligand
Human
NFibrillin-2
ligand
Homo sapiens
NProtein S100-B
ligand
Human
NCalsequestrin-2
ligand
Homo sapiens
NRegucalcin
ligand
Human
NPeflin
ligand
Homo sapiens
UProtein S100-A6
ligand
Human
NTranslationally-controlled tumor protein
ligand
Homo sapiens
UCalcium and integrin-binding family member 2
ligand
Homo sapiens
NProtein S100-A13
ligand
Human
NCalsequestrin-1
ligand
Homo sapiens
UNucleobindin-1
ligand
Homo sapiens
UNucleobindin-2
ligand
Homo sapiens
UCalmodulin
agonist
Human
UFibrillin-3
ligand
Homo sapiens
UGrancalcin
ligand
Homo sapiens
UCalcium-dependent secretion activator 1
agonist
Homo sapiens
UCalmodulin-2
agonist
Homo sapiens
UCalmodulin-3
agonist
Homo sapiens
UProtein S100-A16
ligand
Homo sapiens
UCalretinin
ligand
Homo sapiens
UCalcyphosin
ligand
Homo sapiens
UCalcium-dependent secretion activator 2
agonist
Homo sapiens
UCalreticulin-3
ligand
Homo sapiens
UNeurexin-1
agonist
Human
UNeuronal calcium sensor 1
ligand
Human
Absorption

The percentage of calcium absorbed varies inversely with intake [1]. Tmax of about 3.5-5h varying with formulation [2].

Volume of distribution
Not Available
Protein binding

About 46.4% of calcium is bound to plasma proteins [3].

Metabolism
Not Available
Route of elimination

Cleared via the kidneys but largely reabsorbed (98-99%) under normal conditions [3].

Half life
Not Available
Clearance
Not Available
Toxicity

Patients taking more than 4g of calcium a day are at risk of hypercalcemia and metabolic alkalosis [4]. Chronic intake of calcium supplements is associated with adverse gastrointestinal symptoms such as constipation and flatulence [4] [1].

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinCalcium Citrate may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
AcetyldigoxinCalcium Citrate may increase the arrhythmogenic activities of Acetyldigoxin.Experimental
AgmatineThe therapeutic efficacy of Agmatine can be decreased when used in combination with Calcium Citrate.Experimental, Investigational
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Calcium Citrate.Approved
AlfacalcidolThe risk or severity of adverse effects can be increased when Calcium Citrate is combined with Alfacalcidol.Approved, Nutraceutical
AmiodaroneThe therapeutic efficacy of Amiodarone can be decreased when used in combination with Calcium Citrate.Approved, Investigational
AmlodipineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium Citrate.Approved
AmrinoneThe therapeutic efficacy of Amrinone can be decreased when used in combination with Calcium Citrate.Approved
AranidipineThe therapeutic efficacy of Aranidipine can be decreased when used in combination with Calcium Citrate.Approved, Investigational
AzelnidipineThe therapeutic efficacy of Azelnidipine can be decreased when used in combination with Calcium Citrate.Approved, Investigational
AzimilideThe therapeutic efficacy of Azimilide can be decreased when used in combination with Calcium Citrate.Investigational
BarnidipineThe therapeutic efficacy of Barnidipine can be decreased when used in combination with Calcium Citrate.Approved
BencyclaneThe therapeutic efficacy of Bencyclane can be decreased when used in combination with Calcium Citrate.Experimental
BendroflumethiazideBendroflumethiazide may decrease the excretion rate of Calcium Citrate which could result in a higher serum level.Approved
BenidipineThe therapeutic efficacy of Benidipine can be decreased when used in combination with Calcium Citrate.Approved, Investigational
BenzthiazideBenzthiazide may decrease the excretion rate of Calcium Citrate which could result in a higher serum level.Approved
BepridilThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium Citrate.Approved, Withdrawn
BioallethrinThe therapeutic efficacy of Bioallethrin can be decreased when used in combination with Calcium Citrate.Approved, Experimental
CalcidiolThe risk or severity of adverse effects can be increased when Calcium Citrate is combined with Calcidiol.Approved, Nutraceutical
CalcipotriolThe risk or severity of adverse effects can be increased when Calcium Citrate is combined with Calcipotriol.Approved
CalcitriolThe risk or severity of adverse effects can be increased when Calcium Citrate is combined with Calcitriol.Approved, Nutraceutical
Calcium AcetateThe risk or severity of adverse effects can be increased when Calcium Citrate is combined with Calcium Acetate.Approved, Investigational
CarboxyamidotriazoleThe therapeutic efficacy of Carboxyamidotriazole can be decreased when used in combination with Calcium Citrate.Investigational
CaroverineThe therapeutic efficacy of Caroverine can be decreased when used in combination with Calcium Citrate.Experimental
CeftriaxoneThe risk or severity of adverse effects can be increased when Calcium Citrate is combined with Ceftriaxone.Approved
ChlorothiazideChlorothiazide may decrease the excretion rate of Calcium Citrate which could result in a higher serum level.Approved, Vet Approved
ChlortetracyclineThe serum concentration of Chlortetracycline can be decreased when it is combined with Calcium Citrate.Approved, Investigational, Vet Approved
ChlorthalidoneChlorthalidone may decrease the excretion rate of Calcium Citrate which could result in a higher serum level.Approved
CholecalciferolThe risk or severity of adverse effects can be increased when Calcium Citrate is combined with Cholecalciferol.Approved, Nutraceutical
CilnidipineThe therapeutic efficacy of Cilnidipine can be decreased when used in combination with Calcium Citrate.Approved, Investigational
CinnarizineThe therapeutic efficacy of Cinnarizine can be decreased when used in combination with Calcium Citrate.Approved, Investigational
CinoxacinCalcium Citrate can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
CiprofloxacinCalcium Citrate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
ClevidipineThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium Citrate.Approved, Investigational
Clodronic AcidThe serum concentration of Clodronic Acid can be decreased when it is combined with Calcium Citrate.Approved, Investigational, Vet Approved
CyclandelateThe therapeutic efficacy of Cyclandelate can be decreased when used in combination with Calcium Citrate.Approved
CyclopenthiazideCyclopenthiazide may decrease the excretion rate of Calcium Citrate which could result in a higher serum level.Experimental
CymarinCalcium Citrate may increase the arrhythmogenic activities of Cymarin.Experimental
DarodipineThe therapeutic efficacy of Darodipine can be decreased when used in combination with Calcium Citrate.Experimental
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Calcium Citrate.Approved
DemeclocyclineThe serum concentration of Demeclocycline can be decreased when it is combined with Calcium Citrate.Approved
DeslanosideCalcium Citrate may increase the arrhythmogenic activities of Deslanoside.Approved
DigitoxinCalcium Citrate may increase the arrhythmogenic activities of Digitoxin.Approved, Investigational
DigoxinCalcium Citrate may increase the arrhythmogenic activities of Digoxin.Approved
Digoxin Immune Fab (Ovine)Calcium Citrate may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).Approved
DihydrotachysterolThe risk or severity of adverse effects can be increased when Calcium Citrate is combined with Dihydrotachysterol.Approved
DiltiazemThe therapeutic efficacy of Diltiazem can be decreased when used in combination with Calcium Citrate.Approved, Investigational
Dipotassium phosphateCalcium Citrate can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DobutamineThe therapeutic efficacy of Dobutamine can be decreased when used in combination with Calcium Citrate.Approved
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Calcium Citrate.Approved
DotarizineThe therapeutic efficacy of Dotarizine can be decreased when used in combination with Calcium Citrate.Investigational
DoxercalciferolThe risk or severity of adverse effects can be increased when Calcium Citrate is combined with Doxercalciferol.Approved
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Calcium Citrate.Approved, Investigational, Vet Approved
EfonidipineThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Calcium Citrate.Approved, Investigational
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Calcium Citrate.Approved
EnoxacinCalcium Citrate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EperisoneThe therapeutic efficacy of Eperisone can be decreased when used in combination with Calcium Citrate.Approved, Investigational
EpitizideEpitizide may decrease the excretion rate of Calcium Citrate which could result in a higher serum level.Experimental
ErgocalciferolThe risk or severity of adverse effects can be increased when Calcium Citrate is combined with Ergocalciferol.Approved, Nutraceutical
EstramustineCalcium Citrate can cause a decrease in the absorption of Estramustine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EthosuximideThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Calcium Citrate.Approved
Etidronic acidThe serum concentration of Etidronic acid can be decreased when it is combined with Calcium Citrate.Approved
FelodipineThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium Citrate.Approved, Investigational
FendilineThe therapeutic efficacy of Fendiline can be decreased when used in combination with Calcium Citrate.Withdrawn
Fish oilThe therapeutic efficacy of Fish oil can be decreased when used in combination with Calcium Citrate.Approved, Nutraceutical
FleroxacinCalcium Citrate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FlumequineCalcium Citrate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
FlunarizineThe therapeutic efficacy of Flunarizine can be decreased when used in combination with Calcium Citrate.Approved
FluspirileneThe therapeutic efficacy of Fluspirilene can be decreased when used in combination with Calcium Citrate.Approved, Investigational
GabapentinThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Calcium Citrate.Approved, Investigational
GallopamilThe therapeutic efficacy of Gallopamil can be decreased when used in combination with Calcium Citrate.Investigational
GarenoxacinCalcium Citrate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
GatifloxacinCalcium Citrate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GemifloxacinCalcium Citrate can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GitoformateCalcium Citrate may increase the arrhythmogenic activities of Gitoformate.Experimental
GrepafloxacinCalcium Citrate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
HydrochlorothiazideHydrochlorothiazide may decrease the excretion rate of Calcium Citrate which could result in a higher serum level.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may decrease the excretion rate of Calcium Citrate which could result in a higher serum level.Approved, Investigational
IbandronateThe serum concentration of Ibandronate can be decreased when it is combined with Calcium Citrate.Approved, Investigational
IndapamideIndapamide may decrease the excretion rate of Calcium Citrate which could result in a higher serum level.Approved
IsradipineThe therapeutic efficacy of Isradipine can be decreased when used in combination with Calcium Citrate.Approved, Investigational
LacidipineThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium Citrate.Approved, Investigational
LamotrigineThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium Citrate.Approved, Investigational
Lanatoside CCalcium Citrate may increase the arrhythmogenic activities of Lanatoside C.Experimental
LercanidipineThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Calcium Citrate.Approved, Investigational
LevetiracetamThe therapeutic efficacy of Levetiracetam can be decreased when used in combination with Calcium Citrate.Approved, Investigational
LevofloxacinCalcium Citrate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Calcium Citrate.Approved
LidoflazineThe therapeutic efficacy of Lidoflazine can be decreased when used in combination with Calcium Citrate.Experimental
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Calcium Citrate.Approved, Vet Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Calcium Citrate.Approved
Lipoic AcidCalcium Citrate can cause a decrease in the absorption of Lipoic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Nutraceutical
LomefloxacinCalcium Citrate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LoperamideThe therapeutic efficacy of Loperamide can be decreased when used in combination with Calcium Citrate.Approved
Magnesium sulfateThe therapeutic efficacy of Magnesium sulfate can be decreased when used in combination with Calcium Citrate.Approved, Investigational, Vet Approved
ManidipineThe therapeutic efficacy of Manidipine can be decreased when used in combination with Calcium Citrate.Approved, Investigational
MentholThe therapeutic efficacy of Menthol can be decreased when used in combination with Calcium Citrate.Approved
MethsuximideThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Calcium Citrate.Approved
MethyclothiazideMethyclothiazide may decrease the excretion rate of Calcium Citrate which could result in a higher serum level.Approved
MetildigoxinCalcium Citrate may increase the arrhythmogenic activities of Metildigoxin.Experimental
MetolazoneMetolazone may decrease the excretion rate of Calcium Citrate which could result in a higher serum level.Approved
MibefradilThe therapeutic efficacy of Mibefradil can be decreased when used in combination with Calcium Citrate.Investigational, Withdrawn
MinocyclineThe serum concentration of Minocycline can be decreased when it is combined with Calcium Citrate.Approved, Investigational
MoxifloxacinCalcium Citrate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NaftopidilThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Calcium Citrate.Investigational
Nalidixic AcidCalcium Citrate can cause a decrease in the absorption of Nalidixic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NemonoxacinCalcium Citrate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
NicardipineThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Calcium Citrate.Approved, Investigational
NifedipineThe therapeutic efficacy of Nifedipine can be decreased when used in combination with Calcium Citrate.Approved
NiguldipineThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium Citrate.Experimental
NiludipineThe therapeutic efficacy of Niludipine can be decreased when used in combination with Calcium Citrate.Experimental
NilvadipineThe therapeutic efficacy of Nilvadipine can be decreased when used in combination with Calcium Citrate.Approved, Investigational
NimesulideThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium Citrate.Approved, Investigational, Withdrawn
NimodipineThe therapeutic efficacy of Nimodipine can be decreased when used in combination with Calcium Citrate.Approved, Investigational
NisoldipineThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium Citrate.Approved
NitrendipineThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Citrate.Approved, Investigational
NorfloxacinCalcium Citrate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NylidrinThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Calcium Citrate.Approved
OfloxacinCalcium Citrate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
OleandrinCalcium Citrate may increase the arrhythmogenic activities of Oleandrin.Experimental, Investigational
OtiloniumThe therapeutic efficacy of Otilonium can be decreased when used in combination with Calcium Citrate.Experimental, Investigational
OuabainCalcium Citrate may increase the arrhythmogenic activities of Ouabain.Approved
Oxolinic acidCalcium Citrate can cause a decrease in the absorption of Oxolinic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
OxytetracyclineThe serum concentration of Oxytetracycline can be decreased when it is combined with Calcium Citrate.Approved, Investigational, Vet Approved
PamidronateThe serum concentration of Pamidronate can be decreased when it is combined with Calcium Citrate.Approved
ParicalcitolThe risk or severity of adverse effects can be increased when Calcium Citrate is combined with Paricalcitol.Approved, Investigational
PazufloxacinCalcium Citrate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PefloxacinCalcium Citrate can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PeruvosideCalcium Citrate may increase the arrhythmogenic activities of Peruvoside.Experimental
PinaveriumThe therapeutic efficacy of Pinaverium can be decreased when used in combination with Calcium Citrate.Approved
Pipemidic acidCalcium Citrate can cause a decrease in the absorption of Pipemidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Piromidic acidCalcium Citrate can cause a decrease in the absorption of Piromidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PolythiazidePolythiazide may decrease the excretion rate of Calcium Citrate which could result in a higher serum level.Approved
PrenylamineThe therapeutic efficacy of Prenylamine can be decreased when used in combination with Calcium Citrate.Withdrawn
ProscillaridinCalcium Citrate may increase the arrhythmogenic activities of Proscillaridin.Experimental
PrulifloxacinCalcium Citrate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
QuinethazoneQuinethazone may decrease the excretion rate of Calcium Citrate which could result in a higher serum level.Approved
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Calcium Citrate.Approved, Investigational
RosoxacinCalcium Citrate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
RufloxacinCalcium Citrate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
SeletracetamThe therapeutic efficacy of Seletracetam can be decreased when used in combination with Calcium Citrate.Investigational
SitafloxacinCalcium Citrate can cause a decrease in the absorption of Sitafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
Sodium glycerophosphateCalcium Citrate can cause a decrease in the absorption of Sodium glycerophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium phosphateCalcium Citrate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SparfloxacinCalcium Citrate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Strontium ranelateThe serum concentration of Strontium ranelate can be decreased when it is combined with Calcium Citrate.Approved, Withdrawn
Technetium Tc-99m etidronateThe serum concentration of Technetium Tc-99m etidronate can be decreased when it is combined with Calcium Citrate.Approved
Technetium Tc-99m medronateThe serum concentration of Technetium Tc-99m medronate can be decreased when it is combined with Calcium Citrate.Approved
TemafloxacinCalcium Citrate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
TerodilineThe therapeutic efficacy of Terodiline can be decreased when used in combination with Calcium Citrate.Experimental
TetracyclineThe serum concentration of Tetracycline can be decreased when it is combined with Calcium Citrate.Approved, Vet Approved
TetrahydropalmatineThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Calcium Citrate.Investigational
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Calcium Citrate.Approved
Tiludronic acidThe serum concentration of Tiludronic acid can be decreased when it is combined with Calcium Citrate.Approved, Investigational, Vet Approved
Tolfenamic AcidThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium Citrate.Approved, Investigational
TranilastThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium Citrate.Approved, Investigational
TrichlormethiazideTrichlormethiazide may decrease the excretion rate of Calcium Citrate which could result in a higher serum level.Approved, Vet Approved
TriethylenetetramineThe serum concentration of Triethylenetetramine can be decreased when it is combined with Calcium Citrate.Approved, Investigational
TrimebutineThe therapeutic efficacy of Trimebutine can be decreased when used in combination with Calcium Citrate.Approved
TrimethadioneThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Calcium Citrate.Approved
TrovafloxacinCalcium Citrate can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
VerapamilThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium Citrate.Approved
VinpocetineThe therapeutic efficacy of Vinpocetine can be decreased when used in combination with Calcium Citrate.Investigational
WIN 55212-2The therapeutic efficacy of WIN 55212-2 can be decreased when used in combination with Calcium Citrate.Experimental
ZiconotideThe therapeutic efficacy of Ziconotide can be decreased when used in combination with Calcium Citrate.Approved
Zoledronic acidThe serum concentration of Zoledronic acid can be decreased when it is combined with Calcium Citrate.Approved
ZonisamideThe therapeutic efficacy of Zonisamide can be decreased when used in combination with Calcium Citrate.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Reid IR, Bristow SM, Bolland MJ: Calcium supplements: benefits and risks. J Intern Med. 2015 Oct;278(4):354-68. doi: 10.1111/joim.12394. Epub 2015 Jul 14. [PubMed:26174589]
  2. Heller HJ, Stewart A, Haynes S, Pak CY: Pharmacokinetics of calcium absorption from two commercial calcium supplements. J Clin Pharmacol. 1999 Nov;39(11):1151-4. [PubMed:10579145]
  3. 21. (2012). In Ganong's Review of Medical Physiology (24th ed., pp. 377-385). McGraw Hill. [ISBN:978-0-07-17803-2]
  4. HSDB: Calcium Compounds [Link]
External Links
PubChem Compound
13136
PubChem Substance
347827894
ChemSpider
12584
ChEMBL
CHEMBL2106123
Wikipedia
Calcium_citrate
ATC Codes
A11GB01 — Ascorbic acid (vit c) and calciumA12AA13 — Calcium citrate
FDA label
Download (457 KB)
MSDS
Download (77.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Not Yet RecruitingTreatmentChronic Hypoparathyroidism1
Not AvailableCompletedTreatmentImpaired Renal Function1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral350 mg
Tablet, effervescentOral500 mg
Kit
Tablet, coatedOral
Capsule, liquid filledOral
TabletOral
Tablet, chewableOral
Capsule, gelatin coatedOral
CapsuleOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility4.12 mg/mLALOGPS
logP0.13ALOGPS
logP-1.3ChemAxon
logS-2.1ALOGPS
pKa (Strongest Acidic)3.05ChemAxon
pKa (Strongest Basic)-4.2ChemAxon
Physiological Charge-3ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area140.62 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity68.14 m3·mol-1ChemAxon
Polarizability14.23 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as tricarboxylic acids and derivatives. These are carboxylic acids containing exactly three carboxyl groups.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Tricarboxylic acids and derivatives
Direct Parent
Tricarboxylic acids and derivatives
Alternative Parents
Tertiary alcohols / Carboxylic acid salts / Organic calcium salts / Carboxylic acids / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Tricarboxylic acid or derivatives / Tertiary alcohol / Carboxylic acid salt / Organic calcium salt / Carboxylic acid / Organic oxygen compound / Organic oxide / Hydrocarbon derivative / Organic salt / Organooxygen compound
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
Senses changes in the extracellular concentration of calcium ions. The activity of this receptor is mediated by a G-protein that activates a phosphatidylinositol-calcium second messenger system.
Gene Name
CASR
Uniprot ID
P41180
Uniprot Name
Extracellular calcium-sensing receptor
Molecular Weight
120672.385 Da
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Ligand
General Function
Zinc ion binding
Specific Function
Calcium-binding chaperone that promotes folding, oligomeric assembly and quality control in the endoplasmic reticulum (ER) via the calreticulin/calnexin cycle. This lectin interacts transiently wit...
Gene Name
CALR
Uniprot ID
P27797
Uniprot Name
Calreticulin
Molecular Weight
48141.2 Da
References
  1. UniProt: Calreticulin [Link]
Kind
Protein
Organism
Homo sapiens
Pharmacological action
Unknown
Actions
Ligand
General Function
Calcium-binding protein that plays a role in the regulation of numerous cellular processes, such as cell differentiation, cell division, cell proliferation, cell migration, thrombosis, angiogenesis, cardiac hypertrophy and apoptosis. Involved in bone marrow megakaryocyte differentiation by negatively regulating thrombopoietin-mediated signaling pathway. Participates in the endomitotic cell cycle of megakaryocyte, a form of mitosis in which both karyokinesis and cytokinesis are interrupted. Plays a role in integrin signaling by negatively regulating alpha-IIb/beta3 activation in thrombin-stimulated megakaryocytes preventing platelet aggregation. Up-regulates PTK2/FAK1 activity, and is also needed for the recruitment of PTK2/FAK1 to focal adhesions; it thus appears to play an important role in focal adhesion formation. Positively regulates cell migration on fibronectin in a CDC42-dependent manner, the effect being negatively regulated by PAK1. Functions as a negative regulator of stress activated MAP kinase (MAPK) signaling pathways. Down-regulates inositol 1,4,5-trisphosphate receptor-dependent calcium signaling. Involved in sphingosine kinase SPHK1 translocation to the plasma membrane in a N-myristoylation-dependent manner preventing TNF-alpha-induced apoptosis. Regulates serine/threonine-protein kinase PLK3 activity for proper completion of cell division progression. Plays a role in microtubule (MT) dynamics during neuronal development; disrupts the MT depolymerization activity of STMN2 attenuating NGF-induced neurite outgrowth and the MT reorganization at the edge of lamellipodia. Promotes cardiomyocyte hypertrophy via activation of the calcineurin/NFAT signaling pathway. Stimulates calcineurin PPP3R1 activity by mediating its anchoring to the sarcolemma. In ischemia-induced (pathological or adaptive) angiogenesis, stimulates endothelial cell proliferation, migration and microvessel formation by activating the PAK1 and ERK1/ERK2 signaling pathway. Promotes also cancer cell survival and proliferation. May regulate cell cycle and differentiation of spermatogenic germ cells, and/or differentiation of supporting Sertoli cells.
Specific Function
Calcium ion binding
Gene Name
CIB1
Uniprot ID
Q99828
Uniprot Name
Calcium and integrin-binding protein 1
Molecular Weight
21703.07 Da
References
  1. UniProt: Calcium and integrin-binding protein 1 [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Protein dimerization activity
Specific Function
Calcium-binding protein required for T-cell receptor-, Fas-, and glucocorticoid-induced cell death. May mediate Ca(2+)-regulated signals along the death pathway (By similarity). Calcium-dependent a...
Gene Name
PDCD6
Uniprot ID
O75340
Uniprot Name
Programmed cell death protein 6
Molecular Weight
21868.32 Da
References
  1. Uniprot: Programmed cell death protein 6 [Link]
Kind
Protein
Organism
Homo sapiens
Pharmacological action
Unknown
Actions
Ligand
General Function
Calcium-binding protein that modulates excitation-contraction coupling in the heart. Contributes to calcium homeostasis in the heart sarcoplasmic reticulum. Modulates the activity of RYR2 calcium channels.
Specific Function
Calcium channel regulator activity
Gene Name
SRI
Uniprot ID
P30626
Uniprot Name
Sorcin
Molecular Weight
21676.245 Da
References
  1. UniProt: Sorcin [Link]
Kind
Protein
Organism
Homo sapiens
Pharmacological action
Unknown
Actions
Agonist
General Function
Calcium-binding protein involved in different processes such as regulation of vesicular trafficking, plasma membrane Na(+)/H(+) exchanger and gene transcription. Involved in the constitutive exocytic membrane traffic. Mediates the association between microtubules and membrane-bound organelles of the endoplasmic reticulum and Golgi apparatus and is also required for the targeting and fusion of transcytotic vesicles (TCV) with the plasma membrane. Functions as an integral cofactor in cell pH regulation by controlling plasma membrane-type Na(+)/H(+) exchange activity. Affects the pH sensitivity of SLC9A1/NHE1 by increasing its sensitivity at acidic pH. Required for the stabilization and localization of SLC9A1/NHE1 at the plasma membrane. Inhibits serum- and GTPase-stimulated Na(+)/H(+) exchange. Plays a role as an inhibitor of ribosomal RNA transcription by repressing the nucleolar UBF1 transcriptional activity. May sequester UBF1 in the nucleoplasm and limit its translocation to the nucleolus. Associates to the ribosomal gene promoter. Acts as a negative regulator of the calcineurin/NFAT signaling pathway. Inhibits NFAT nuclear translocation and transcriptional activity by suppressing the calcium-dependent calcineurin phosphatase activity. Also negatively regulates the kinase activity of the apoptosis-induced kinase STK17B. Inhibits both STK17B auto- and substrate-phosphorylations in a calcium-dependent manner.
Specific Function
Calcium ion binding
Gene Name
CHP1
Uniprot ID
Q99653
Uniprot Name
Calcineurin B homologous protein 1
Molecular Weight
22455.96 Da
References
  1. UniProt: Calcineurin B homologous protein 1 [Link]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Ligand
General Function
Extracellular matrix binding
Specific Function
Appears to regulate cell growth through interactions with the extracellular matrix and cytokines. Binds calcium and copper, several types of collagen, albumin, thrombospondin, PDGF and cell membran...
Gene Name
SPARC
Uniprot ID
P09486
Uniprot Name
SPARC
Molecular Weight
34631.88 Da
References
  1. UniProt: SPARC [Link]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Ligand
General Function
Poly(a) rna binding
Specific Function
Calcium-binding protein that interacts with newly synthesized glycoproteins in the endoplasmic reticulum. It may act in assisting protein assembly and/or in the retention within the ER of unassembl...
Gene Name
CANX
Uniprot ID
P27824
Uniprot Name
Calnexin
Molecular Weight
67567.695 Da
References
  1. UniProt: Calnexin [Link]
Kind
Protein
Organism
Homo sapiens
Pharmacological action
No
Actions
Ligand
General Function
Fibrillin-2: Fibrillins are structural components of 10-12 nm extracellular calcium-binding microfibrils, which occur either in association with elastin or in elastin-free bundles. Fibrillin-2-containing microfibrils regulate the early process of elastic fiber assembly. Regulates osteoblast maturation by controlling TGF-beta bioavailability and calibrating TGF-beta and BMP levels, respectively.
Specific Function
Calcium ion binding
Gene Name
FBN2
Uniprot ID
P35556
Uniprot Name
Fibrillin-2
Molecular Weight
314772.155 Da
References
  1. UniProt: Fibrillin-2 [Link]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Ligand
General Function
Zinc ion binding
Specific Function
Weakly binds calcium but binds zinc very tightly-distinct binding sites with different affinities exist for both ions on each monomer. Physiological concentrations of potassium ion antagonize the b...
Gene Name
S100B
Uniprot ID
P04271
Uniprot Name
Protein S100-B
Molecular Weight
10712.985 Da
References
  1. UniProt: Protein S100-B [Link]
Kind
Protein
Organism
Homo sapiens
Pharmacological action
No
Actions
Ligand
General Function
Calsequestrin is a high-capacity, moderate affinity, calcium-binding protein and thus acts as an internal calcium store in muscle. Calcium ions are bound by clusters of acidic residues at the protein surface, especially at the interface between subunits. Can bind around 60 Ca(2+) ions. Regulates the release of lumenal Ca(2+) via the calcium release channel RYR2; this plays an important role in triggering muscle contraction. Plays a role in excitation-contraction coupling in the heart and in regulating the rate of heart beats.
Specific Function
Calcium ion binding
Gene Name
CASQ2
Uniprot ID
O14958
Uniprot Name
Calsequestrin-2
Molecular Weight
46435.28 Da
References
  1. UniProt: Calsequestrin-2 [Link]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Ligand
General Function
Zinc ion binding
Specific Function
Gluconolactonase with low activity towards other sugar lactones, including gulonolactone and galactonolactone. Can also hydrolyze diisopropyl phosphorofluoridate and phenylacetate (in vitro). Calci...
Gene Name
RGN
Uniprot ID
Q15493
Uniprot Name
Regucalcin
Molecular Weight
33252.53 Da
References
  1. UniProt: Regucalcin [Link]
Kind
Protein
Organism
Homo sapiens
Pharmacological action
No
Actions
Ligand
General Function
Calcium-binding protein that acts as an adapter that bridges unrelated proteins or stabilizes weak protein-protein complexes in response to calcium. Together with PDCD6, acts as calcium-dependent adapter for the BCR(KLHL12) complex, a complex involved in endoplasmic reticulum (ER)-Golgi transport by regulating the size of COPII coats (PubMed:27716508). In response to cytosolic calcium increase, the heterodimer formed with PDCD6 interacts with, and bridges together the BCR(KLHL12) complex and SEC31 (SEC31A or SEC31B), promoting monoubiquitination of SEC31 and subsequent collagen export, which is required for neural crest specification (PubMed:27716508). Its role in the heterodimer formed with PDCD6 is however unclear: some evidences show that PEF1 and PDCD6 work together and promote association between PDCD6 and SEC31 in presence of calcium (PubMed:27716508). Other reports show that PEF1 dissociates from PDCD6 in presence of calcium, and may act as a negative regulator of PDCD6 (PubMed:11278427). Also acts as a negative regulator of ER-Golgi transport; possibly by inhibiting interaction between PDCD6 and SEC31 (By similarity).
Specific Function
Binding, bridging
Gene Name
PEF1
Uniprot ID
Q9UBV8
Uniprot Name
Peflin
Molecular Weight
30380.755 Da
References
  1. UniProt: Peflin [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Ligand
General Function
Zinc ion binding
Specific Function
May function as calcium sensor and modulator, contributing to cellular calcium signaling. May function by interacting with other proteins, such as TPR-containing proteins, and indirectly play a rol...
Gene Name
S100A6
Uniprot ID
P06703
Uniprot Name
Protein S100-A6
Molecular Weight
10179.635 Da
References
  1. UniProt: Protein S100-A6 [Link]
Kind
Protein
Organism
Homo sapiens
Pharmacological action
No
Actions
Ligand
General Function
Involved in calcium binding and microtubule stabilization.
Specific Function
Calcium ion binding
Gene Name
TPT1
Uniprot ID
P13693
Uniprot Name
Translationally-controlled tumor protein
Molecular Weight
19595.205 Da
References
  1. UniProt: Translationally-controlled tumor protein [Link]
Kind
Protein
Organism
Homo sapiens
Pharmacological action
Unknown
Actions
Ligand
General Function
Calcium-binding protein critical for proper photoreceptor cell maintenance and function. Plays a role in intracellular calcium homeostasis by decreasing ATP-induced calcium release (PubMed:23023331, PubMed:26173970, PubMed:26426422). May be involved in the mechanotransduction process (By similarity).
Specific Function
Calcium ion binding
Gene Name
CIB2
Uniprot ID
O75838
Uniprot Name
Calcium and integrin-binding family member 2
Molecular Weight
21643.38 Da
References
  1. UniProt: Calcium and integrin-binding family member 2 [Link]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Ligand
General Function
Zinc ion binding
Specific Function
Plays a role in the export of proteins that lack a signal peptide and are secreted by an alternative pathway. Binds two calcium ions per subunit. Binds one copper ion. Binding of one copper ion doe...
Gene Name
S100A13
Uniprot ID
Q99584
Uniprot Name
Protein S100-A13
Molecular Weight
11471.095 Da
References
  1. UniProt: Protein S100-A13 [Link]
Kind
Protein
Organism
Homo sapiens
Pharmacological action
No
Actions
Ligand
General Function
Calsequestrin is a high-capacity, moderate affinity, calcium-binding protein and thus acts as an internal calcium store in muscle. Calcium ions are bound by clusters of acidic residues at the protein surface, often at the interface between subunits. Can bind around 80 Ca(2+) ions. Regulates the release of lumenal Ca(2+) via the calcium release channel RYR1; this plays an important role in triggering muscle contraction.
Specific Function
Calcium ion binding
Gene Name
CASQ1
Uniprot ID
P31415
Uniprot Name
Calsequestrin-1
Molecular Weight
45159.635 Da
References
  1. UniProt: Calsequestrin-1 [Link]
Kind
Protein
Organism
Homo sapiens
Pharmacological action
Unknown
Actions
Ligand
General Function
Major calcium-binding protein of the Golgi. May have a role in calcium homeostasis (By similarity).
Specific Function
Calcium ion binding
Gene Name
NUCB1
Uniprot ID
Q02818
Uniprot Name
Nucleobindin-1
Molecular Weight
53878.96 Da
References
  1. UniProt: Nucleobindin-1 [Link]
Kind
Protein
Organism
Homo sapiens
Pharmacological action
Unknown
Actions
Ligand
General Function
Calcium-binding protein. May have a role in calcium homeostasis.
Specific Function
Calcium ion binding
Gene Name
NUCB2
Uniprot ID
P80303
Uniprot Name
Nucleobindin-2
Molecular Weight
50195.385 Da
References
  1. UniProt: Nucleobindin-2 [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Titin binding
Specific Function
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number...
Gene Name
CALM1
Uniprot ID
P0DP23
Uniprot Name
Calmodulin
Molecular Weight
16837.47 Da
References
  1. UniProt: Calmodulin-1 [Link]
Kind
Protein
Organism
Homo sapiens
Pharmacological action
Unknown
Actions
Ligand
General Function
Fibrillin-3: Fibrillins are structural components of 10-12 nm extracellular calcium-binding microfibrils, which occur either in association with elastin or in elastin-free bundles. Fibrillin-containing microfibrils provide long-term force bearing structural support.
Specific Function
Calcium ion binding
Gene Name
FBN3
Uniprot ID
Q75N90
Uniprot Name
Fibrillin-3
Molecular Weight
300352.86 Da
References
  1. UniProt: Fibrillin-3 [Link]
Kind
Protein
Organism
Homo sapiens
Pharmacological action
Unknown
Actions
Ligand
General Function
Calcium-binding protein that may play a role in the adhesion of neutrophils to fibronectin. May play a role in the formation of focal adhesions.
Specific Function
Calcium ion binding
Gene Name
GCA
Uniprot ID
P28676
Uniprot Name
Grancalcin
Molecular Weight
24009.85 Da
References
  1. UniProt: Grancalcin [Link]
Kind
Protein
Organism
Homo sapiens
Pharmacological action
Unknown
Actions
Agonist
General Function
Calcium-binding protein involved in exocytosis of vesicles filled with neurotransmitters and neuropeptides. Probably acts upstream of fusion in the biogenesis or maintenance of mature secretory vesicles. Regulates catecholamine loading of DCVs. May specifically mediate the Ca(2+)-dependent exocytosis of large dense-core vesicles (DCVs) and other dense-core vesicles by acting as a PtdIns(4,5)P2-binding protein that acts at prefusion step following ATP-dependent priming and participates in DCVs-membrane fusion. However, it may also participate in small clear synaptic vesicles (SVs) exocytosis and it is unclear whether its function is related to Ca(2+) triggering (By similarity).
Specific Function
Lipid binding
Gene Name
CADPS
Uniprot ID
Q9ULU8
Uniprot Name
Calcium-dependent secretion activator 1
Molecular Weight
152785.36 Da
References
  1. UniProt: Calcium-dependent secretion activator 1 [Link]
Kind
Protein
Organism
Homo sapiens
Pharmacological action
Unknown
Actions
Agonist
General Function
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins through calcium-binding. Among the enzymes to be stimulated by the calmodulin-calcium complex are a number of protein kinases and phosphatases. Together with CCP110 and centrin, is involved in a genetic pathway that regulates the centrosome cycle and progression through cytokinesis (PubMed:16760425). Mediates calcium-dependent inactivation of CACNA1C (PubMed:26969752). Positively regulates calcium-activated potassium channel activity of KCNN2 (PubMed:27165696).
Specific Function
Calcium channel inhibitor activity
Gene Name
CALM2
Uniprot ID
P0DP24
Uniprot Name
Calmodulin-2
Molecular Weight
16837.47 Da
References
  1. UniProt: Calmodulin-2 [Link]
Kind
Protein
Organism
Homo sapiens
Pharmacological action
Unknown
Actions
Agonist
General Function
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins through calcium-binding. Among the enzymes to be stimulated by the calmodulin-calcium complex are a number of protein kinases and phosphatases. Together with CCP110 and centrin, is involved in a genetic pathway that regulates the centrosome cycle and progression through cytokinesis.
Specific Function
Calcium ion binding
Gene Name
CALM3
Uniprot ID
P0DP25
Uniprot Name
Calmodulin-3
Molecular Weight
16837.47 Da
References
  1. UniProt: Calmodulin-3 [Link]
Kind
Protein
Organism
Homo sapiens
Pharmacological action
Unknown
Actions
Ligand
General Function
Calcium-binding protein. Binds one calcium ion per monomer.
Specific Function
Calcium ion binding
Gene Name
S100A16
Uniprot ID
Q96FQ6
Uniprot Name
Protein S100-A16
Molecular Weight
11801.3 Da
References
  1. UniProt: Protein S100-A16 [Link]
Kind
Protein
Organism
Homo sapiens
Pharmacological action
Unknown
Actions
Ligand
General Function
Calretinin is a calcium-binding protein which is abundant in auditory neurons.
Specific Function
Calcium ion binding
Gene Name
CALB2
Uniprot ID
P22676
Uniprot Name
Calretinin
Molecular Weight
31539.62 Da
References
  1. UniProt: Calretinin [Link]
Kind
Protein
Organism
Homo sapiens
Pharmacological action
Unknown
Actions
Ligand
General Function
Calcium-binding protein. May play a role in cellular signaling events (Potential).
Specific Function
Calcium ion binding
Gene Name
CAPS
Uniprot ID
Q13938
Uniprot Name
Calcyphosin
Molecular Weight
20967.15 Da
References
  1. UniProt: Calcyphosin [Link]
Kind
Protein
Organism
Homo sapiens
Pharmacological action
Unknown
Actions
Agonist
General Function
Calcium-binding protein involved in exocytosis of vesicles filled with neurotransmitters and neuropeptides. Probably acts upstream of fusion in the biogenesis or maintenance of mature secretory vesicles. Regulates neurotrophin release from granule cells leading to regulate cell differentiation and survival during cerebellar development. May specifically mediate the Ca(2+)-dependent exocytosis of large dense-core vesicles (DCVs) and other dense-core vesicles (By similarity).
Specific Function
Lipid binding
Gene Name
CADPS2
Uniprot ID
Q86UW7
Uniprot Name
Calcium-dependent secretion activator 2
Molecular Weight
147733.365 Da
References
  1. UniProt: Calcium-dependent secretion activator 2 [Link]
Kind
Protein
Organism
Homo sapiens
Pharmacological action
Unknown
Actions
Ligand
General Function
During spermatogenesis, may act as a lectin-independent chaperone for specific client proteins such as ADAM3. Required for sperm fertility (By similarity). CALR3 capacity for calcium-binding may be absent or much lower than that of CALR.
Specific Function
Calcium ion binding
Gene Name
CALR3
Uniprot ID
Q96L12
Uniprot Name
Calreticulin-3
Molecular Weight
44995.345 Da
References
  1. UniProt: Calreticulin-3 [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Receptor activity
Specific Function
Cell surface protein involved in cell-cell-interactions, exocytosis of secretory granules and regulation of signal transmission. Function is isoform-specific. Alpha-type isoforms have a long N-term...
Gene Name
NRXN1
Uniprot ID
Q9ULB1
Uniprot Name
Neurexin-1
Molecular Weight
161881.53 Da
References
  1. UniProt: Neurexin-1 [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Ligand
General Function
Voltage-gated calcium channel activity
Specific Function
Neuronal calcium sensor, regulator of G protein-coupled receptor phosphorylation in a calcium dependent manner. Directly regulates GRK1 (RHOK), but not GRK2 to GRK5. Can substitute for calmodulin (...
Gene Name
NCS1
Uniprot ID
P62166
Uniprot Name
Neuronal calcium sensor 1
Molecular Weight
21878.565 Da
References
  1. UniProt: Neuronal calcium sensor 1 [Link]

Carriers

Kind
Protein
Organism
Homo sapiens
Pharmacological action
No
Actions
Substrate
General Function
Buffers cytosolic calcium. May stimulate a membrane Ca(2+)-ATPase and a 3',5'-cyclic nucleotide phosphodiesterase.
Specific Function
Calcium ion binding
Gene Name
CALB1
Uniprot ID
P05937
Uniprot Name
Calbindin
Molecular Weight
30024.82 Da
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Vitamin d binding
Specific Function
Not Available
Gene Name
S100G
Uniprot ID
P29377
Uniprot Name
Protein S100-G
Molecular Weight
9016.14 Da
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Barrett KE, Barman SM, Boitano S, Brooks HL (2012). Ganong's Review of Medical Physiology (24th ed.). McGraw Hill. [ISBN:978-0-07-17803-2]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Calmodulin binding
Specific Function
Calcium selective cation channel probably involved in Ca(2+) uptake in various tissues, including Ca(2+) reabsorption in intestine. The channel is activated by low internal calcium level, probably ...
Gene Name
TRPV6
Uniprot ID
Q9H1D0
Uniprot Name
Transient receptor potential cation channel subfamily V member 6
Molecular Weight
87284.86 Da
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Ion channel binding
Specific Function
Mediates the exchange of one Ca(2+) ion against three to four Na(+) ions across the cell membrane, and thereby contributes to the regulation of cytoplasmic Ca(2+) levels and Ca(2+)-dependent cellul...
Gene Name
SLC8A1
Uniprot ID
P32418
Uniprot Name
Sodium/calcium exchanger 1
Molecular Weight
108546.06 Da
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Calcium channel activity
Specific Function
Constitutively active calcium selective cation channel thought to be involved in Ca(2+) reabsorption in kidney and intestine. The channel is activated by low internal calcium level and the current ...
Gene Name
TRPV5
Uniprot ID
Q9NQA5
Uniprot Name
Transient receptor potential cation channel subfamily V member 5
Molecular Weight
82549.89 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Voltage-gated calcium channel activity
Specific Function
Calcium channel that mediates the release of Ca(2+) from the sarcoplasmic reticulum into the cytoplasm and thereby plays a key role in triggering muscle contraction following depolarization of T-tu...
Gene Name
RYR1
Uniprot ID
P21817
Uniprot Name
Ryanodine receptor 1
Molecular Weight
565170.715 Da
References
  1. UniProt: Ryanodine receptor 1 [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Suramin binding
Specific Function
Calcium channel that mediates the release of Ca(2+) from the sarcoplasmic reticulum into the cytoplasm and thereby plays a key role in triggering cardiac muscle contraction. Aberrant channel activa...
Gene Name
RYR2
Uniprot ID
Q92736
Uniprot Name
Ryanodine receptor 2
Molecular Weight
564562.71 Da
References
  1. UniProt: Ryanodine receptor 2 [Link]
Kind
Protein
Organism
Homo sapiens
Pharmacological action
Unknown
Actions
Substrate
General Function
Pore-forming subunit of a ciliary calcium channel that controls calcium concentration within primary cilia without affecting cytoplasmic calcium concentration. Forms a heterodimer with PKD1L1 in primary cilia and forms a calcium-permeant ciliary channel that regulates sonic hedgehog/SHH signaling and GLI2 transcription. May act as a sour taste receptor by forming a calcium channel with PKD1L3 in gustatory cells; however, its contribution to sour taste perception is unclear in vivo and may be indirect.
Specific Function
Alpha-actinin binding
Gene Name
PKD2L1
Uniprot ID
Q9P0L9
Uniprot Name
Polycystic kidney disease 2-like 1 protein
Molecular Weight
91981.23 Da
References
  1. UniProt: Polycystic kidney disease 2-like 1 protein [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Ryanodine-sensitive calcium-release channel activity
Specific Function
Calcium channel that mediates the release of Ca(2+) from the sarcoplasmic reticulum into the cytoplasm in muscle and thereby plays a role in triggering muscle contraction. May regulate Ca(2+) relea...
Gene Name
RYR3
Uniprot ID
Q15413
Uniprot Name
Ryanodine receptor 3
Molecular Weight
552037.115 Da
References
  1. UniProt: Ryanodine receptor 3 [Link]
Kind
Protein
Organism
Homo sapiens
Pharmacological action
Unknown
Actions
Substrate
General Function
Component of a calcium channel. May act as a sour taste receptor by forming a calcium channel with PKD1L3 in gustatory cells; however, its contribution to sour taste perception is unclear in vivo and may be indirect.
Specific Function
Calcium channel activity
Gene Name
PKD1L3
Uniprot ID
Q7Z443
Uniprot Name
Polycystic kidney disease protein 1-like 3
Molecular Weight
195891.885 Da
References
  1. UniProt: Polycystic kidney disease protein 1-like 3 [Link]
Kind
Protein
Organism
Homo sapiens
Pharmacological action
Unknown
Actions
Substrate
General Function
Voltage-gated calcium channel that plays a central role in calcium-dependent physiological responses essential for successful fertilization, such as sperm hyperactivation, acrosome reaction and chemotaxis towards the oocyte.
Specific Function
Calcium activated cation channel activity
Gene Name
CATSPER1
Uniprot ID
Q8NEC5
Uniprot Name
Cation channel sperm-associated protein 1
Molecular Weight
90090.225 Da
References
  1. UniProt: Cation channel sperm-associated protein 1 [Link]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...

Components:
References
  1. Catterall WA: Structure and regulation of voltage-gated Ca2+ channels. Annu Rev Cell Dev Biol. 2000;16:521-55. [PubMed:11031246]
Kind
Protein group
Organism
Homo sapiens
Pharmacological action
Unknown
Actions
Substrate
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...

Components:
References
  1. Catterall WA: Structure and regulation of voltage-gated Ca2+ channels. Annu Rev Cell Dev Biol. 2000;16:521-55. [PubMed:11031246]
Kind
Protein group
Organism
Homo sapiens
Pharmacological action
Unknown
Actions
Substrate
General Function
Scaffold protein binding
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...

Components:
References
  1. Catterall WA: Structure and regulation of voltage-gated Ca2+ channels. Annu Rev Cell Dev Biol. 2000;16:521-55. [PubMed:11031246]
Kind
Protein group
Organism
Homo sapiens
Pharmacological action
Unknown
Actions
Substrate
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...

Components:
References
  1. Catterall WA: Structure and regulation of voltage-gated Ca2+ channels. Annu Rev Cell Dev Biol. 2000;16:521-55. [PubMed:11031246]

Drug created on December 03, 2015 09:51 / Updated on June 02, 2018 09:45